echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Pfizer's new crown oral drug was clinically successful, Merck’s stock price fell nearly 10%, and neutralizing antibody and vaccine stocks fell again across the board

    Pfizer's new crown oral drug was clinically successful, Merck’s stock price fell nearly 10%, and neutralizing antibody and vaccine stocks fell again across the board

    • Last Update: 2021-11-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, new crown oral drugs have continued to welcome good news


    From: Pfizer official website


    Vaccine stocks and neutralizing antibody concept stocks once again fell across the board following the positive development of oral drugs
    .
    New crown vaccine stock leaders Moderna and BioNTech both saw their biggest declines today by more than 24%, while Curevac and Novavax fell by about 8% and 12%, respectively
    .
    Neutralizing antibody stock Vir Biotechnology fell 15%, Regeneron fell 6%, and Eli Lilly, which also owns New Crown Neutral, also fell 3%
    .
    Vaccine stocks share price changes in the past 5 days


    Moderna is the vaccine stock that has suffered the most recently
    .
    On Thursday, Moderna's third quarterly report announced that due to capacity constraints, its vaccines only achieved sales of 4.
    8 billion U.
    S.
    dollars.
    The annual production capacity and sales expectations were both lowered, which immediately caused a nearly 20% share price drop
    .
    The next day, following the announcement of Pfizer's new crown oral drug data, it fell by nearly 20%.
    In the past two days, it has fallen by nearly 40%, and its market value has evaporated by nearly 50 billion
    .
    With turbulence on the new crown track, Pfizer has undoubtedly become a true leader, achieving dual coverage of vaccines and oral drugs .
    The third-quarter report released on Tuesday showed that the company’s mRNA vaccine cooperation with BioNTech achieved quarterly sales of 13 billion U.
    S.
    dollars, and annual sales are expected to reach 36 billion U.
    S.
    dollars; now oral drugs have obtained clinical data significantly better than Merck’s, and even comparable to those in China.
    And antibodies .
    According to industry insiders, the follow-up market for vaccines is still broad, while neutralizing antibodies are limited.
    Pfizer's data can be regarded as a dimensional reduction blow for neutralizing antibodies .





    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.